Share this article
Share this article
International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression
Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants
TORONTO, June 9, 2021 /PRNewswire/ - Braxia Scientific Corp. ( Braxia , or the Company ), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance (the Guidelines ) for the clinical use of rapi
Braxia Scientific team-led guidelines into clinical uses of ketamine and esketamine published in prestigious American Journal of Psychiatry
Its CEO Roger McIntyre and medical director Joshua Rosenblat led a team of experts to develop the International Expert Opinion and Implementation Guidance for the clinical use of rapid-acting ketamine and esketamine for treatment-resistant depression Esketamine therapy received FDA approval with breakthrough status in 2019
Braxia Scientific Corp (CSE:BRAX) (OTCMKTS:BRAXF) (FRA:496) CEO Roger McIntyre saw his research into the clinical uses of ketamine and esketamine published in the prestigious American Journal of Psychiatry.
McIntyre and Braxia’s medical director Joshua Rosenblat led a team of 26 experts to develop the International Expert Opinion and Implementation Guidance (Guidelines) for the clinical use of rapid-acting Ketamine and Esketamine for treatment-resistant depression, according to Braxia.
E-Mail
A new study at the University of Chicago Medicine and Washington University found that a single inhalation session with 25% nitrous oxide gas was nearly as effective as 50% nitrous oxide at rapidly relieving symptoms of treatment-resistant depression, with fewer adverse side effects. The study, published June 9 in
Science Translational Medicine, also found that the effects lasted much longer than previously suspected, with some participants experiencing improvements for upwards of two weeks.
These results bolster the evidence that non-traditional treatments may be a viable option for patients whose depression is not responsive to typical antidepressant medications. It may also provide a rapidly effective treatment option for patients in crisis.
NA Proactive news snapshot: NEO Battery Materials, Organic Garage, Unigold, Braxia Scientific, Starton Therapeutics …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
NEO Battery Materials Ltd (CVE:NBM) (OTCMKTS:NBMFF) recently announced that its s silicon (Si) nanocoating technology successfully achieved an ultra-fast charging/discharging capability in a half-cell coin test. Following a new test conducted by the laboratory of Dr Jong Hyeok Park, who is also Neo s chief scientific advisor, the company said the “breakthrough results” showed the potency of NEO s nanocoating technology through “superior charging/discharging performance on small battery cells.” Significantly, NEO s nanocoated silicon anode allows for “a safe full charge within 5 minutes,” which demonstrates potential for scaling and implementation in larger cells such as those used in high power E